This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by el-Farrash, M A Articles by Harada, S Search for Related Content PubMed PubMed Citation Articles by el-Farrash, M A Articles by Harada, S

 Previous Article  |  Next Article 

J Virol. 1994 January; 68(1): 233-239

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.

Department of Biodefence and Medical Virology, Kumamoto University School of Medicine, Japan.

ABSTRACT

A synthetic peptide, RPI 312, that specifically inhibits the protease of the human immunodeficiency virus type 1 (HIV-1) showed a potent inhibition on virus production, maturation, and infectivity. Treatment with this agent prevented the cleavage of Gag protein at the site between p17 and p24 in HIV-1 chronically infected MOLT-4 cells as well as in the released virus. Passage of HIV-1 in the presence of gradually increasing concentrations of this protease inhibitor resulted in emergence of a variant that could evade the drug effects. In the resistant variant the maturation of Gag proteins appeared normal, but its infectivity was reduced compared with that of the parent virus. The nucleotides coding the amino acids at and around the cleavage site between Gag proteins p17 and p24 were not changed. One point mutation (A-->G) at site 2082 of the pol gene that resulted in one amino acid change at site 84 of the protease from isoleucine to valine (I-84-->V) could be detected in the resistant variant. An HIV-1 infectious DNA clone with the I-84-->V mutation also showed reduced sensitivity to this protease inhibitor. The findings that the resistant variant had lower infectivity and was still affected by higher doses of the drug support the speculation that resistance to protease inhibitors may not be as problematic as other drug resistance.

This article has been cited by other articles:

• Nishitsuji, H., Kohara, M., Kannagi, M., Masuda, T. (2006). Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration.. J. Virol. 80: 7658-7666 [Abstract] [Full Text]  
• Yusa, K., Song, W., Bartelmann, M., Harada, S. (2002). Construction of a Human Immunodeficiency Virus Type 1 (HIV-1) Library Containing Random Combinations of Amino Acid Substitutions in the HIV-1 Protease due to Resistance by Protease Inhibitors. J. Virol. 76: 3031-3037 [Abstract] [Full Text]  
• Julias, J. G., Pathak, V. K. (1998). Deoxyribonucleoside Triphosphate Pool Imbalances In Vivo Are Associated with an Increased Retroviral Mutation Rate. J. Virol. 72: 7941-7949 [Abstract] [Full Text]  
• Fujiwara, T., Sato, A., El-Farrash, M., Miki, S., Abe, K., Isaka, Y., Kodama, M., Wu, Y., Chen, L. B., Harada, H., Sugimoto, H., Hatanaka, M., Hinuma, Y. (1998). S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 42: 1340-1345 [Abstract] [Full Text]  
• Ala, P. J., DeLoskey, R. J., Huston, E. E., Jadhav, P. K., Lam, P. Y. S., Eyermann, C. J., Hodge, C. N., Schadt, M. C., Lewandowski, F. A., Weber, P. C., McCabe, D. D., Duke, J. L., Chang, C.-H. (1998). Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors. J. Biol. Chem. 273: 12325-12331 [Abstract] [Full Text]  
• Flexner, C. (1998). HIV-Protease Inhibitors. NEJM 338: 1281-1293 [Full Text]  
• Nureki, O., Vassylyev, D. G., Tateno, M., Shimada, A., Nakama, T., Fukai, S., Konno, M., Hendrickson, T. L., Schimmel, P., Yokoyama, S. (1998). Enzyme Structure with Two Catalytic Sites for Double-Sieve Selection of Substrate. Science 280: 578-582 [Abstract] [Full Text]  
• Schock, H. B., Garsky, V. M., Kuo, L. C. (1996). Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials. COMPENSATORY MODULATIONS OF BINDING AND ACTIVITY. J. Biol. Chem. 271: 31957-31963 [Abstract] [Full Text]  
• Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., Livingston, D. J. (1996). Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants. J. Biol. Chem. 271: 17979-17985 [Abstract] [Full Text]  
• Ridky, T., Leis, J. (1995). Development of Drug Resistance to HIV-1 Protease Inhibitors. J. Biol. Chem. 270: 29621-29623 [Full Text]  
• Menéndez-Arias, L., Weber, I. T., Oroszlan, S. (1995). Mutational Analysis of the Substrate Binding Pocket of Murine Leukemia Virus Protease and Comparison with Human Immunodeficiency Virus Proteases. J. Biol. Chem. 270: 29162-29168 [Abstract] [Full Text]